Study 200195 App’s purpose is to support GSK Study 200195 (Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Registry for Patients Treated with Strimvelis™ (or GSK269273) Gene Therapy: Long-Term Prospective, Non-Interventional Follow-up of Safety and Effectiveness). Registry participant’s will be able to use the app to enter the required information for the study.
- Glaxo SmithKline PLC
- 54.8 MB
Requires iOS 9.0 or later. Compatible with iPhone, iPad and iPod touch.
- Age Rating
- Rated 12+ for the following:
- Infrequent/Mild Medical/Treatment Information
- © GSK PLC
Up to six family members will be able to use this app with Family Sharing enabled.